India: Government caps prices of new drugs to treat diabetes, hypertension - (The Times of India via NewsPoints Desk)

  • India's National Pharmaceutical Pricing Authority (NPPA) has fixed the prices of 18 new drugs in accordance with the Drugs Price Control Order (DPCO) 2013, as reported The Times of India Monday.
  • The drugs affected by price fixation include therapies for diseases such as hypertension and diabetes manufactured by companies including Alembic Pharma, Cipla, Merck & Co. and Unichem.
  • The NPPA stated that any company that fails to comply with the order "shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013."
  • The DPCO 2013 initially fixed the prices of 652 branded products based on 348 formulations of essential medicines, although industry experts noted that the order has since come to affect more than 700 products.
  • In the current order, the NPPA also explained that if any company had priced an essential medicine below the fixed price, it should continue to maintain the existing lower price.

To read more NewsPoints articles, click here.

Reference Articles